MOVISCOM addressed its research projects towards the study of rare metabolic diseases and cooperates with highly-qualified professionals, comprised of internationally renowned experts. A line of specific products has been developed to treat rare genetic diseases such as Hyperphenylalaninemia (HPA) and Phenylketonuria (PKU).

MOVISCOM pays constant attention to the assessment of efficacy and safety of its products supporting focused clinical research programs. Cooperations with local and international partners and research centers are an important source of projects to increase the product portfolio and to guarantee the quality of the manufactured products.